medigraphic.com
ISSN 1729-519X (Print)

2020, Number 6

<< Back Next >>

Revista Habanera de Ciencias Médicas 2020; 19 (6)

Current status of Cannabis sativa; therapeutic benefits and adverse reactions

Rodríguez-Venegas EC, Fontaine-Ortiz JE

Language: Spanish
References: 45
Page: 1-17
PDF size: 793.78 Kb.


ABSTRACT

Introduction: Currently, one of the most controversial issues that greatly involves the medical field is the therapeutic use and legalization of marijuana. This millennial recognition has led to different controversies in recent decades due to the discovery of the endocannabinoid system which has revolutionized the process of research on this topic.
Objective: To describe the current situation of cannabis, its therapeutic benefits and adverse effects.
Material and methods: An in-depth search and review was carried out using Health Sciences descriptors in English and Spanish. A search was carried out in PubMed, SciELO, Lilacs, Cochrane Library and Web of Science databases. Publications from the last 10 years were consulted, using a total of 45 articles as bibliographic references.
Development: Some pharmacological effects such as antinociceptive, antiepileptic, immunosuppressive, antiemetic, appetite stimulant, antimicrobial, anti-inflammatory and neuroprotective ones have been attributed to Cannabis. In turn, it presents dissimilar adverse reactions such as predisposition to various types of cancer, worsening of mental disorders, and difficulties with learning and school performance. Cannabis, among others, is considered a starter drug. Despite the trend towards legalization, there are not enough reasons for the legalization of this drug. Its main target turns out to be the adolescents, among which the neurological damage it causes is irreversible.
Conclusions: The therapeutic potential of cannabinoids should continue to be explored from the production of well dosed and controlled pharmacological products, since the risk of their adverse effects are undeniable and overwhelming.


REFERENCES

  1. Rodríguez R. Los productos de Cannabis sativa: situación actual y perspectivas en medicina. Salud Mental [Internet]. 2012 [Citado 20/07/2019];35(3):247-56. Disponible en: Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0185-33252012000300009

  2. Cardeillac V. Cannabis y esquizofrenia: Revisión de la literatura de los últimos quince años. Rev Psiquiatr Urug [Internet]. 2016 [Citado 20/07/2019];80(1):33-44. Disponible en: Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-973339

  3. Fernández Artamendi S, Fernández Hermida J, Secades Villa R, García Portilla P. Cannabis y Salud Mental. Actas Esp Psiquiatr [Internet]. 2011 [Citado 20/07/2019];39(3):180-90. Disponible en: Disponible en: https://medes.com/publication/66243

  4. Kilmer B. Recreational Cannabis - Minimizing the Health Risks from Legalization. N Engl J Med [Internet]. 2017 [Citado 20/07/2019];376:705-7. Disponible en: Disponible en: http://doi.org/10.1056/NEJMp1614783

  5. Ángeles GE, Brindis F, Cristians S, Ventura R. Cannabis sativa L., una planta singular. Rev Mex Cienc Farm [Internet]. 2014 [Citado 20/07/2019];45(4):[Aprox: 8 p.]. Disponible en: Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1870-01952014000400004

  6. Muñoz E. Cannabis en el tratamiento del dolor crónico no oncológico. Rev Hosp Clín Univ Chile [Internet]. 2015 [Citado 20/07/2019];26:138-47. Disponible en: Disponible en: https://www.redclinica.cl/Portals/0/Users/014/14/14/cannabis_en_tratamiento-dolor.pdf

  7. Philippe MA. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs [Internet]. 2012 [Citado 20/07/2019];44(2):125-33. Disponible en: Disponible en: http://doi.org/10.1080/02791072.2012.684624

  8. Avello M, Pastene E, Fernández P, Córdova P. Potencial uso terapéutico de cannabis. Rev Med Chile [Internet]. 2017 [Citado 20/07/2019];145(3):360-7. Disponible en: Disponible en: http://doi.org/10.4067/S0034-98872017000300010

  9. Landa L, Jurica J, Slivad J, Pechackovae M, Demlovaa R. Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub [Internet]. 2018 [Citado 20/07/2019];162(1):18-25. Disponible en: Disponible en: https://doi.org/10.5507/bp.2018.007

  10. Aloi J, Blair KS, Crum KI, Meffert H, White SF, Tyler PM, et al. Adolescents show differential dysfunctions related to Alcohol and Cannabis Use Disorder severity in emotion and executive attention neuro-circuitries. NeuroImage: Clinical [Internet]. 2018 [Citado 20/07/2019];19:782-92. Disponible en: Disponible en: https://doi.org/10.1016/j.nicl.2018.06.005

  11. Nadal X, La Porta C, Andreea S, Maldonado R. Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol [Internet]. 2013 [Citado 20/07/2019];716(1-3):142-57. Disponible en: Disponible en: http://doi.org/10.1016/j.ejphar.2013.01.007

  12. Lau BK, Vaughan CW. Targeting the endogenous cannabinoid system to treat neuropathic pain. Frontiers in Pharmacology [Internet]. 2014 [Citado 20/07/2019];5:28. Disponible en: Disponible en: http://doi.org/10.3389/fphar.2014.00028

  13. Whiting PF, Wolff R, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA [Internet]. 2015 [Citado 20/07/2019];313(24):2456-73. Disponible en: Disponible en: http://doi.org/10.1001/jama.2015.6358

  14. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, et al. Building a new conceptual frame work for receptor heteromers. Nat Chem Biol [Internet]. 2009 [Citado 20/07/2019];5(3):131-4. Disponible en: Disponible en: http://doi.org/10.1038/nchembio0309-131

  15. Del Bosque J, Fernández C, Sánchez R, Díaz DB, Gutiérrez AD, Fuentes A. El problema del consumo de cannabis: el papel del Sector Salud. Salud Mental [Internet]. 2013 [Citado 20/07/2019];36(2)149-58. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=41632

  16. Méndez M, Ruiz AE, Prieto B, Romano A. El cerebro y las drogas, sus mecanismos neurobiológicos. Salud Mental [Internet]. 2010 [Citado 20/07/2019];33(5):451-6. Disponible en: Disponible en: www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0185-33252010000500009

  17. Freeman T, Hindocha C, Green S, Bloomfield M. Medicinal use of cannabis based products and cannabinoids. BMJ [Internet]. 2019 [Citado 20/07/2019];365:1141. Disponible en: Disponible en: http://doi.org/10.1136/bmj.l1141

  18. Hoch E, Niemann D, Von Keller R, Schneider M, Friemel CM, Preuss UW, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch of Psych and Clin Neuroscience [Internet]. 2019 [Citado 20/07/2019];269:87-105. Disponible en: Disponible en: https://doi.org/10.1007/s00406-019-00984-4

  19. Nanni RI, Del Campo RM, Villamil V. Therapeutic properties of cannabinoid drugs and marijuana in several disorders: A narrative review. Salud Mental [Internet]. 2017 [Citado 20/07/2019];40(3):111-8. Disponible en: Disponible en: http://doi.org/10.17711/SM.0185-3325. 2017.014

  20. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology [Internet]. 2014 [Citado 20/07/2019];82(17):1556-63. Disponible en: Disponible en: http://doi.org/10.1212/WNL.0000000000000363

  21. Moulin D, Boulanger A, Clark AJ. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag [Internet]. 2014 [Citado 20/07/2019];19(6):328-35. Disponible en: Disponible en: http://doi.org/10.1155/2014/754693

  22. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology [Internet]. 2007 [Citado 20/07/2019];68(7):515-21. Disponible en: Disponible en: http://doi.org/10.1212/01.wnl.0000253187.66183.9c

  23. Committee of the Health Effects of Marijuana. An evidence review and research agenda. The health effects of cannabis and cannabinoids. The current state of evidence and recommendations for research. [Internet]. Washington: National Academies Press; 2017 [Citado 20/07/2019]. Disponible en: Disponible en: https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state

  24. Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain [Internet]. 2018 [Citado 20/07/2019];19(1):37. Disponible en: Disponible en: https://doi.org/10.1186/s10194-018-0862-2

  25. Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy [Internet]. 2016 [Citado 20/07/2019];36(5):505-10. Disponible en: Disponible en: http://doi.org/10.1002/phar.1673

  26. Lochte BC, Beletsky A, Samuel NK, Grant I. The use of cannabis for headache disorders. Cannabis Cannabinoid Res [Internet]. 2017 [Citado 20/07/2019];2(1):61-71. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436334/

  27. Bauer F, Donahoo W, Hollis H, Tsai A, Pottorf B, Johnson J. Marijuana’s Influence on Pain Scores, Initial Weight Loss, and Other Bariatric Surgical Outcomes. Perm J [Internet]. 2018 [Citado 23/07/2019];22:18-20. Disponible en: Disponible en: https://doi.org/10.7812/TPP/18-002

  28. Volkow N, Baler R, Compton W, Weiss S. Adverse Health Effects of Marijuana Use. N Engl J Med [Internet]. 2018 [Citado 23/07/2019];370:2219-27. Disponible en: Disponible en: http://doi.org/10.1056/NEJMra1402309

  29. Martínez L, Tacoronte JE, Núñez Y, Montalbán M, Cabrera HR. Potencial terapéutico de los canabinoides como neuroprotectores. Rev Cubana Farm [Internet]. 2007 [Citado 23/07/2019];41(3):[Aprox 6 p.]. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152007000300012

  30. Simonienko K, Wygnał N, Cwalina U, Kwiatkowski M, Szulc M, Waszkiewicz N. The reasons for use of cannabinoids and stimulants in patients with schizophrenia. Psychiatr Pol [Internet]. 2018 [Citado 23/07/2019];52(2):261-73. Disponible en: Disponible en: https://doi.org/10.12740/PP/68472

  31. European Monitoring Centre for Drugs and Drug Addiction. Medical use of cannabis and cannabinoids: questions and answers for policymaking [Internet]. Luxembourg: Publications Office of the European Union; 2018 [Citado 23/07/2019]. Disponible en: Disponible en: http://www.emcdda.europa.eu/system/files/publications/10171/20185584_TD0618186ENN_PDF.pdf

  32. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet [Internet]. 2009 [Citado 20/07/2019];374(9698):1383-91. Disponible en: Disponible en: https://doi.org/10.1016/S0140-6736(09)61037-0

  33. Prandi C, Blangetti M, Namda D, Koltai H. Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases. Molecules [Internet]. 2018 [Citado 23/07/2019];23(7):1526. Disponible en: Disponible en: http://doi.org/10.3390/molecules23071526

  34. Richter K, Levy S. Big Marijuana - Lessons from Big Tobacco. N Engl J Med [Internet]. 2014 [Citado 23/07/2019];371(5):399-401. Disponible en: Disponible en: http://doi.org/10.1056/NEJMp1406074

  35. González RA, Donaire IA. Marihuana: Posibles Beneficios vs. Tragedias Cotidianas. La Habana: Editorial Academia; 2017.

  36. World Health Organization: Expert Committee on Drug Dependence. Cannabidiol (CBD) Pre-Review Report [Internet]. Geneva: OMS; 2016 [Citado 23/07/2019]. Disponible en: Disponible en: http://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf

  37. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology [Internet]. 2016 [Citado 23/07/2019];15(3):270-8. Disponible en: Disponible en: http://doi.org/10.1016/S1474-4422(15)00379-8

  38. Sewell RA, Skosnik PD, García Sosa I, Ranganathan M, D’Souza DC. Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia. Rev Bras Psiquiatr [Internet]. 2010 [Citado 23/07/2019];32(Suppl 1):S15-S30. Disponible en: Disponible en: https://psycnet.apa.org/record/2011-21819-002

  39. Mena I, Dörr A, Viani S, Neubauer S, Gorostegui ME, Dörr MP, et al. Efectos del consumo de marihuana en escolares sobre funciones cerebrales demostrados mediante pruebas neuropsicológicas e imágenes de neuro-SPECT. Salud Mental [Internet]. 2018 [Citado 23/07/2019];36(5):367-74. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=46536

  40. Bowles DW, O’Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol [Internet]. 2012 [Citado 20/07/2019];83(1):1-10. Disponible en: Disponible en: http://doi.org/10.1016/j.critrevonc.2011.09.008

  41. Borowska M, Czarnywojtek A, Sawicka Gutaj N, Woliński K, Płazińska MT, Mikołajczak P. The effects of cannabinoids on the endocrine system. Endokrynologia Polska [Internet]. 2018 [Citado 23/07/2019];69(6):705-19. Disponible en: Disponible en: http://doi.org/10.5603/EP.a2018.0072

  42. Reisfield G, Dupont R. Medicinal Use of Marijuana: Recommend against the Medicinal Use of Marijuana. N Eng J Med [Internet]. 2013 [Citado 23/07/2019];368:866-8. Disponible en: Disponible en: http://doi.org/10.1056/NEJMclde1300970

  43. National Institute for Health and Care Excellence. Do Not Do Recommendations: Sativex to treat spasticity in people with MS because it is not a cost effective treatment [Internet]. Manchester: National Institute for Health and Care Excellence; 2014 [Citado 23/07/2019]. Disponible en: Disponible en: https://www.nice.org.uk/donotdo/do-not-offer-sativex-to-treat-spasticity-in-people-with-ms-because-it-is-not-a-cost-effective-treatment

  44. Food and Drug Administration. Highlights of prescribing information: EPIDIOLEX. [Internet]. United States: Food and Drug Administration; 2018 [Citado 23/07/2019]. Disponible en: Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf

  45. Royal College of General Practitioners. Cannabis-based medicines: an interim desktop guide [Internet]. London: Royal College of General Practitioners; 2018[Citado 23/07/2019]. Disponible en: Disponible en: https://www.rcgp.org.uk/clinical-and-research/resources/a-to-z-clinicalresources/cannabis-based-medication.aspx




2020     |     www.medigraphic.com